Compared with non-NAFLD, participants with NAFLD exhibited worse metabolic indicators, including serum lipid, FPG, HbA1c, BMI, uric acid, and waist circumference, as well as higher prevalence of metabolic complications such as hypertension and diabetes, higher alanine transaminase level, more severe steatosis and fibrosis judged by CAP and LSM values. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.